Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas

Br J Cancer. 2018 Sep;119(6):661-662. doi: 10.1038/s41416-018-0218-3. Epub 2018 Aug 21.

Authors

Inês Pires da Silva^{1

2}, Marcel Batten^{1

2}, Georgina V Long^{3

4

5}

Affiliations

¹ Melanoma Institute Australia, Sydney, NSW, Australia.
² Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
³ Melanoma Institute Australia, Sydney, NSW, Australia. Georgina.Long@melanoma.org.au.
⁴ Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. Georgina.Long@melanoma.org.au.
⁵ Royal North Shore Hospital, Sydney, NSW, Australia. Georgina.Long@melanoma.org.au.

No abstract available

Publication types

Editorial

MeSH terms

Clinical Trials as Topic
Combined Modality Therapy
Drug Resistance, Neoplasm
Humans
Immunotherapy
Lymphocytes, Tumor-Infiltrating / immunology
Lymphocytes, Tumor-Infiltrating / transplantation*
Melanoma / immunology
Melanoma / therapy*
Tumor Microenvironment